| Single residue variation in skeletal muscle myosin enables direct and selective drug targeting for spasticity and muscle stiffness M Gyimesi, ÁI Horváth, D Túrós, SK Suthar, M Pénzes, C Kurdi, L Canon, ... Cell 183 (2), 335-346. e13, 2020 | 31 | 2020 |
| Titin activates myosin filaments in skeletal muscle by switching from an extensible spring to a mechanical rectifier C Squarci, P Bianco, M Reconditi, I Pertici, M Caremani, T Narayanan, ... Proceedings of the National Academy of Sciences 120 (9), e2219346120, 2023 | 11 | 2023 |
| Effect of allosteric inhibition of non-muscle myosin 2 on its intracellular diffusion ÁI Horváth, M Gyimesi, BH Várkuti, M Képiró, G Szegvári, I Lőrincz, ... Scientific Reports 10 (1), 13341, 2020 | 9 | 2020 |
| Investigation of the relationships between material properties and processing parameters of boron micro-alloyed quenched and tempered steels J Loerinczi, G Kralik, M Kovacs, A Horvath Materials Science Forum 414, 2003 | 9 | 2003 |
| The New-Generation Muscle Relaxant MPH-220 Dissolves Spasticity in Muscles After Cns Injury-a Promising Drug to Address Post-Stroke Spasticity M Gyimesi, AI Horvath, D Túrós, G Hegyi, SK Suthar, M Kovacs, ... Biophysical Journal 118 (3), 434a, 2020 | 1 | 2020 |
| In vivo KCNH2-suppression-replacement gene therapy attenuates the pathogenic phenotype in transgenic rabbits with short QT syndrome type 1 S Nimani, S Bains, N Alerni, L Giammarino, J Louradour, A Horvath, ... Europace 26 (Supplement_1), euae102. 630, 2024 | | 2024 |
| In vivo KCNQ1-suppression-replacement gene therapy in transgenic LQT1 rabbits restores a physiological QT interval at baseline and under catecholamine infusion L Giammarino, S Bains, J Louradour, S Nimani, N Alerni, D Tester, ... Europace 26 (Supplement_1), euae102. 605, 2024 | | 2024 |
| SGK1 inhibition normalizes action potential duration in transgenic LQT2 rabbits but not in LQT1, suggesting a novel gene-specific therapeutic approach in long QT syndrome M Barbieri, J Lourdaour, N Alerni, L Giammarino, S Nimani, L Matas, ... Cardiovascular Research 120 (Supplement_1), cvae088. 024, 2024 | | 2024 |
| Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms A Málnási-Csizmadia, M Gyimesi, A Szabó, P Hári, SS Kumar, M Kovács, ... US Patent 11,845,758, 2023 | | 2023 |
| Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms A Málnási-Csizmadia, M Gyimesi, A Szabó, P Hári, SS Kumar, M Kovács, ... US Patent 11,746,112, 2023 | | 2023 |
| Titin function in the active sarcomere studied in frog muscle fibers upon inhibition of myosin motors by para-nitro-blebbistatin C Squarci, P Bianco, M Reconditi, I Pertici, M Caremani, T Narayanan, ... Biophysical Journal 122 (3), 29a, 2023 | | 2023 |
| Regulation of APD and force by Na+/Ca2+ exchanger in hiPSC-cardiomyocytes D Ismaili, K Gurr, A Horvath, L Yuan, MD Lemoine, C Schulz, J Sani, ... Europace 24 (Supplement_1), euac053. 625, 2022 | | 2022 |
| The role of NM2 rearrangement during cytokinesis AI Horvath, M Gyimesi, M Kepiro, B Varkuti, A Malnasi-Csizmadia Biophysical Journal 121 (3), 259a-260a, 2022 | | 2022 |
| Application of neural-network-based deep-learning analysis to reveal changes of the movement parameters in rat neuromuscular disorder models M Winternitz, M Gyimesi, AI Horvath, M Penzes, A Malnasi-Csizmadia Biophysical Journal 121 (3), 258a-259a, 2022 | | 2022 |
| Passive and active mechanical properties of titin studied in intact frog muscle fibers upon inhibition of myosin motors by para-nitro-blebbistatin C Squarci, P Bianco, M Reconditi, I Pertici, M Caremani, T Narayanan, ... Biophysical Journal 121 (3), 515a, 2022 | | 2022 |
| First-in-class drug candidate (MPH-220) efficiently improves spastic gait disorders by selective inhibition of fast skeletal muscle myosin-2 M Gyimesi, AI Horvath, D Turos, SK Suthar, M Penzes, L Canon, C Kikuti, ... Biophysical Journal 121 (3), 291a, 2022 | | 2022 |
| Culture conditions effect properties of the Na+/K+-ATPase pump current in hiPSC cardiomyocytes D Ismaili, K Gurr, A Horvath, A Hansen, T Eschenhagen, T Christ EP Europace 23 (Supplement_3), euab116. 577, 2021 | | 2021 |
| Abstract P221: First-In-Class Anti-Spastic Drug Candidate (MPH-220) Efficiently Relaxes Spastic Muscles and Improves Motor Functions in Gait Disorder in Preclinical Studies M Gyimesi, A Horvath, D Turos, M Penzes, C Kurdi, M Kovacs, ... Stroke 52 (Suppl_1), AP221-AP221, 2021 | | 2021 |
| First-In-Class Anti-Spastic Drug Candidate (MPH-220) Efficiently Relaxes Spastic Muscles and Improves Motor Functions in Gait Disorder in Preclinical Studies. M Gyimesi, A Horvath, D Turos, M Penzes, C Kurdi, M Kovacs, ... STROKE 52, 2021 | | 2021 |
| NEW-GENERATION ANTI-SPASTIC DRUG CANDIDATE (MPH-220) IMPROVES MOTOR FUNCTIONS OF SPASTIC RATS WITH BRAIN DAMAGE M Gyimesi, A Horvath, D Turos, M Penzes, C Kurdi, A Szabo, M Kovacs, ... INTERNATIONAL JOURNAL OF STROKE 15 (1_ SUPPL), 266-266, 2020 | | 2020 |
